IXICO Targets Go-To Status In Neuro Data Analytics Space

Neuroscience data specialist IXICO has broad ambitions to partner with pharmas large and small, helping them develop better-targeted clinical trials using imaging and digital biomarker data. A business review in late 2017 by CEO Giulio Cerroni refined the company’s value proposition, while keeping the headline elements in place: scale the business and diversify within neuroscience.

Cerroni_Giulio
IXICO CEO Giulio Cerroni

The neuroscience data analytics company Ixico Ltd. is many things to many people, but it is not a start-up. CEO of two years Giulio Cerroni stresses that almost before we start. IXICO is also not an especially young company, formed some 14 years ago as a spin-out from several UK universities, it has been trading for 13 years, and in 2018 (year-end September 30) reported an underlying revenue increase of 41% and a record-high revenue total of £5.4m ($7.02m). It has been AIM-listed since its 2013 reverse takeover of Phytopharm.

The company’s performance to date has been good, but it is not good enough for Cerroni. On assuming the chief...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Innovation

More from In Vivo